Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 0.10% is 52% below its 5-year average of 0.20%, near the low end of its 5-year range (0.00%–0.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 41.78% below its 12-month average of 0.17%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.10%.
DEBT TO ASSETS RATIO
0.10%
DEBT TO ASSETS RATIO AVG TTM
0.17%
DEBT TO ASSETS RATIO AVG 3Y
0.29%
DEBT TO ASSETS RATIO AVG 5Y
0.20%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-41.78%
CURRENT VS 3Y AVG
-66.54%
CURRENT VS 5Y AVG
-51.74%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 536 covered companies
CURRENT VS SECTOR MEDIAN
-3.32%
vs the sector median at left
GH Research PLC
Market Cap
$1.50B
Debt to Assets Ratio
0.10%
TTM Avg
0.17%
3Y Avg
0.29%
5Y Avg
0.20%
Market Cap
$1.51B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.47B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.50B | 0.10% | 0.17% | 0.29% | 0.20% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.51B | 0.25% | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.48B | 0.11% | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.53B | 0.16% | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 0.02% | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.45B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 0.85% | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.58B | 0.21% | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | 0.03% | N/A | N/A | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.39B | 0.01% | N/A | N/A | N/A |
Debt/Assets
0.1%
Debt/Equity
0.00
Current Ratio
28.70
Interest Coverage
-131.1x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 0.10% |
| 2026-03-31 | 0.16% |
| 2025-12-31 | 0.18% |
| 2025-09-30 | 0.19% |
| 2025-06-30 | 0.21% |
| 2025-03-31 | 0.21% |
| 2024-12-31 | 0.33% |
| 2024-09-30 | 0.37% |
| 2024-06-30 | 0.37% |
| 2024-03-31 | 0.41% |
| 2023-12-31 | 0.43% |
| 2023-09-30 | 0.40% |
| 2023-06-30 | 0.42% |
| 2023-03-31 | 0.45% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
